Channel/transporter | Â | Cell type | Changes | EMF type | Parameter (frequency/intensity) | References |
---|---|---|---|---|---|---|
TRPC1 | TRPC1 | MSC | Increased | PEMF | 10 min, 0–3 mT | [20] |
TRPC1 | TRPC1 | Myoblasts | Increased | PEMF | 10Â min, 1.5 mT | [52] |
Purinergic receptor | P2X7 | Mesenchymal stem cells | Increased | EMF | 7.5Â Hz, 15Â Hz, 50Â Hz,75Â Hz/1 mT | [53] |
T-type VGCC | Cav3·2 CACNA1H | Hepatocellular carcinoma cells (tumor stem cells) | Increased | AM RF EMF | 27·12 MHz | [22] |
T-type VGCC | CACNA1H | Breast cancer cells (tumor stem cells) | Increased | AM RF EMF | 27.12Â MHz | [21] |
VGCC | Â | Hippocampus | Decreased | RF-EMF | 835Â MHz | [32] |
L-type VGCC | Â | neurons | Increased | PEMF | 50Â Hz/1 mT | [54] |
T-type VGCC | Â | B16F10 Cancer Cells | Increased | ELF-EMF | 7.83Â Hz | [55] |
L-type VGCC | ||||||
T-type VGCC |  | B16-BL6, MDA-MB-231, MCF-7, and HeLa cells | Increased | EMF | 25–6 Hz | [44] |
T-type VGCC | Cav3.1, Cav3.2 Cav3.3 | HEK293 cells | Decreased | ELF-EMF | 50Â Hz/0.2 mT | [56] |
Ca2+-ATPase | SERCA2a | Cardiomyocytes | Increased | ELF-EMF | 15Â Hz, 50Â Hz, 75Â Hz and 100Â Hz/2 mT | [39] |